Oral lichen planus and its relationship with systemic diseases.
A review of evidence

Juliana Cassol-Spanemberg 1, María-Eugenia Rodríguez-de Rivera-Campillo 2, Eva-María Otero-Rey 3, Albert Estrugo-Devesa 4, Enric Jané-Salas 4, José López-López 5

1 PhD. Postdoctoral Research Fellow. Specialist in Stomatology and Public Health. Faculty of Medicine and Health Sciences (School of Dentistry), University of Barcelona, Spain
2 MD, DDS, PhD, Dermatologist and Dentist. Professor of Oral Pathology, Faculty of Medicine and Health Sciences (School of Dentistry), University of Barcelona / Oral Health and Masticatory System Group (Bellvitge Biomedical Research Institute) IDIBELL, University of Barcelona, Spain
3 DDS, PhD, Odontology. Professor of Master of Daily Practice Dentistry. Department of Stomatology. School of Dentistry. University of Santiago de Compostela, Spain
4 MD, DDS, PhD. Doctor, Specialist in Stomatology. Professor of Oral Pathology, Faculty of Medicine and Health Sciences (School of Dentistry), University of Barcelona / Oral Health and Masticatory System Group (Bellvitge Biomedical Research Institute) IDIBELL, University of Barcelona, Spain
5 MD, DDS, PhD. Doctor, Specialist in Stomatology. Professor of Oral Pathology, Faculty of Medicine and Health Sciences (School of Dentistry), University of Barcelona - Head of the Medical Surgical Area and Medical Director of Dentistry Hospital Barcelona University / Oral Health and Masticatory System Group (Bellvitge Biomedical Research Institute) IDIBELL, University of Barcelona, Spain

Correspondence:
Department of Odontoestomatology
Faculty of Medicine and Health Sciences (School of Dentistry)
Camus Bellvitge, University of Barcelona
18575jll@gmail.com

Received: 14/07/2018
Accepted: 06/08/2018

Abstract
Background: Oral lichen planus (OLP) is one of the most common dermatological diseases which are present in the oral cavity. It is a chronic autoimmune, mucocutaneous disease that affects the oral mucosa as well as the skin, genital mucosa and other sites.
Objective: Review the relevant information to OLP and its relationship with systemic diseases.
Material and Methods: Searches were carried out in the Medline/PubMed, Lilacs, Bireme, BVS, and SciELO databases by using key-words. After an initial search that provided us with 243 papers, this number was reduced to 78 from the last seven years. One of the first criteria adopted was a selective reading of the abstracts of articles for the elimination of publications that presented less information regarding the subject proposed for this work. All the selected articles were read in their entirety by all of the authors, who came to a consensus about their level of evidence. The Scottish Intercollegiate Guidelines Network (SIGN) criteria were used as the criteria of methodological validation.
Results: Only 9 articles showed an evidence level of 1+, 2+, 3 or 4, as well as a recommendation level of A, B, C or D. Three of them were non-systematic reviews, one was a cohort study and only one was a controlled clinical trial. Three of the studies were case series, with respective sample sizes of 45, 171 and 633 patients.
Conclusions: Several factors have been associated with OLP. Patients with OLP are carriers of a disease with systemic implications and may need the care of a multidisciplinary team. The correct diagnosis of any pathology is critical to making effective treatment and minimizes iatrogenic harm. For OLP is no different, taking into account its association with numerous systemic diseases that require special attention from health professionals. Periodic follow-up of all patients with OLP is recommended.

**Key words:** Oral lichen planus, etiopathogenesis, systemic diseases.

**Introduction**

Lichen planus (LP) is a chronic inflammatory mucocutaneous disease that evolves in outbreaks, affecting the skin, mucous membranes or both. It is recurrent and of unknown etiology (1). It tends to adopt different morphologies and experience unpredictable periods of remission and exacerbation (2). It is the dermatological disease that most often presents oral manifestations (3). The exclusive oral presentation of the disease occurs in one out of every three patients, with the three most frequent locations of the buccal mucosa, the tongue and gums (2-4). Oral lichen planus (OLP) may adopt different clinical forms (5,6) and the presentations can be singular or combined. Each one of them has specific features. Its manifestations typically persist for years at a time, alternating between periods of latency and periods of exacerbation (7).

The etiology of this disease remains unknown, but various causal factors have been associated to this disease, among such factors are: anxiety, diabetes, autoimmune diseases, mainly chronic liver disease, intestinal diseases, increased cholesterol, medications, stress, hypertension, infections, contact with dental materials, cancer and a genetic predisposition to cancer (2,3,8-10). Therefore, the diagnosis of OLP must be based on the recognition of the clinical manifestations, as well as the performance of anamnesis in search of a possible cause and effect relationship (7,11). Finally, a histopathological study must be performed in order to enable us to confirm the diagnosis (7).

Based on what has been previously stated, the aim of this paper is to review the information that is relevant to oral lichen planus and its relationship with systemic diseases, as well as briefly review its clinical features and etiology.

**Material and Methods**

-Literature Search Strategy

Searches were carried out in the Medline/PubMed, Lilacs, Bireme, BV, and SciELO databases by using the words: oral lichen planus and systemic diseases, oral lichen planus and hepatitis C virus, diabetes and oral lichen planus, autoimmune diseases and oral lichen planus, chronic diseases and oral lichen planus, intestinal disease and oral lichen planus, cholesterol and oral lichen planus, medications and oral lichen planus, hypertension and oral lichen planus, anxiety and oral lichen planus, stress and oral lichen planus, infections and oral lichen planus in the title and/or abstract. One of the first criteria adopted was a selective reading of the abstracts of articles for the elimination of publications that presented less information regarding the subject proposed for this work.

-Selection, Inclusion Criteria, Data Extraction and Assessment of quality

After an initial search that provided us with 243 papers, this number was reduced to 78 from the last seven years. From there, we used the inclusion criteria of “English and free full text” which gave us a total of 22 papers. These 22 were read in their entirety by all of the authors, who came to a consensus about their level of evidence. Those that were not considered relevant to this review by two or more authors were discarded. The Scottish Intercollegiate Guidelines Network (SIGN) criteria were used as the criteria of methodological validation (12).

**Results**

Only 9 of the 22 articles that were reviewed showed an evidence level of 1+, 2+, 3 or 4, as well as a recommendation level of A, B, C or D (Table 1, 1 continue). Three of them were non-systematic reviews, one was a cohort study and only one was a controlled clinical trial. Three of the studies were case series, with respective sample sizes of 45, 171 and 633 patients.

**Discussion**

For the discussion of the reviewed literature we will use the papers referenced in Table 1 as well as bibliography of prior interest. We will review the most relevant aspects based on: i) concept and epidemiology, ii) clinical features, iii) etiology and iv) the relationship with systemic diseases.

-Concept and Epidemiology

Lichen planus is a chronic inflammatory dermatosis of autoimmune origin that usually manifests in the oral mucosa. The exact prevalence of OLP is unknown, however different sources report a prevalence of between 0.2% and 5% (13), without racial predominance (14). For every one man, 3 or 4 women are diagnosed with the disease (14), but despite the higher prevalence among women, no link...
Table 1: Summary of the eight articles that met the inclusion criteria. The level of evidence for each article is specified. The Scottish Intercollegiate Guidelines Network (SIGN) criteria were used as the criteria of methodological validation (12).

| Article          | Evidence Level (SIGN) | Most representative aspects of the paper                                                                 | Most relevant conclusions                                                                                                                                                                                                 |
|------------------|-----------------------|---------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| De Carli et al.  | 2+                    | - Longitudinal clinical trial<br>- They evaluated the correlation between hepatitis C virus infection and OLP, and further examined the relationship between age, sex, systemic diseases and drugs with the presence of HCV infection or OLP. | There was a significant relationship between HCV infection and manifestation of OLP. Age, sex, systemic diseases and drugs were not identified as risk factors for the development of these diseases. |
| Bascones-Martinez et al. (2014) | 4 | -Review.<br>- They present the adverse effects of the immunomodulatory drugs that can endanger the quality of life of the treated patients. They also study the impact of immunomodulation on the development of oral diseases. | They review the current knowledge on new immunomodulatory drugs from the oral health perspective. They indicate that these drugs seem safe with respect to possible interactions with commonly-used medicine in the dental practice (antibiotics, analgesics and local anesthetics). Nevertheless, interactions may occur with some antifungal medications. They state that new immunomodulatory drugs may also have a role in the treatment of certain oral diseases like oral lichen planus or Sjögren syndrome, without promising results. There are no randomized controlled trials on this topic. |
| Srinivas et al.  | 4                    | -Review.<br>- They present a narrative review that only focuses on the aspects of the etiology and pathogenesis of oral lichen planus. | They state that the interaction of diverse factors is probably responsible for the initiation, aggravation and persistence of OLP. The current treatment modalities are not just inadequate in the treatment and the prevention of recurrences in all the patients, but they also have significant side effects. They report that clarifying the pathogenesis would help to establish therapeutic criteria, thus improving the morbidity of the patients with OLP. |
| Carrozzo & Scally (2014) | 4 | -Review.<br>- They present a narrative review on the extrahepatic manifestations with oral manifestations that are related to the HCV infection. | They review the oral clinical features such as the extrahepatic manifestations of the HCV infection in oral lichen planus, Sjögren syndrome and oral carcinoma. They state that there is epidemiological proof that supports the association between OLP and HCV. They analyze the degree in which HCV can duplicate in the oral mucosa and attract T lymphocytes; such aspects are possibly involved in the pathogenesis of OLP. |
| Munde et al.     | 2+                    | -Cohort study.<br>- They describe the epidemiological characteristics and the clinical condition of 128 patients with OLP in a rural population of India. | In the 128 patients there were 1.6 women for each man. The oral mucosa was the most frequent location (88.20%). The white lichen (reticular form) was observed in the 83.59% of patients and the red lichen in 16.40% of the cases (erosive forms in the 15.6% and atrophic forms in 0.78%). The incidence rate of systemic diseases was 11% for hypertension, 2.4% for diabetes mellitus and 0.78% for the hypothyroidism. Epithelial dysplasia was referenced in four cases. |
| Kumar et al.     | 3                     | -Case series.<br>- They examine a group of patients with OLP for the simultaneous presence of a hepatitis B and C virus infection. | They study 45 clinical cases with histological confirmation of OLP, which are examined for HBV and HCV by means of the ELISA test. None of the patients showed seropositivity for the virus. The authors conclude that there is no link between OLP and the hepatitis B and C viral infections. |
Table 1 continue: Summary of the eight articles that met the inclusion criteria. The level of evidence for each article is specified. The Scottish Intercollegiate Guidelines Network (SIGN) criteria were used as the criteria of methodological validation (12).

| Authors         | Level of Evidence | Study Type              | Description                                                                 |
|-----------------|-------------------|-------------------------|-----------------------------------------------------------------------------|
| Kaplan et al.   | 3                 | Case series             | Is a 10-year retrospective study that evaluates the treatment results and the frequency of malignant transformation. | The study includes 171 patients. Of these 171 patients, 49.5% showed changes in the clinical presentation. The difference between the patients treated and the patients that weren't treated were not significant. The patients with or without systemic diseases required the same treatment for the oral lesions. The prevalence of carcinoma was 5.8% and the malignant transformation can occur in any of the presentation forms. The effect of the systemic diseases was insignificant in this study. The results indicate that all of the clinical forms need monitoring by a clinician. |
| Tovaru et al.   | 2+                | Case series             | They review the medical records of 633 patients with OLP in a population of Romania. | It is the first study carried out on a Romanian population. There was a predominance of OLP among white middle-aged women and prevalence of bilateral affection of the oral mucous membrane with reticular white lesions. The circulating anti-HCV antibodies were more common than in the general population. OLP is also associated with gallbladder disease (cholecystitis, cholelithiasis) in 19% of patients. |
| Hirota et al.   | 1+                | Controlled clinical trial | They research if the systemic medication and/or daily topical medication contributes to the development of oral lichen planus lesions in 110 patients with OLP and 76 control subjects. | It seems that the use of systemic medication does not cause a significant increase in the incidence of OLP lesions. With respect to the medication-induced lichenoid reactions, it is possible for them to only occur in a low percentage of patients. |

*CDG* (chronic desquamative gingivitis) is a non-specific process in which may appear in other mucocutaneous diseases, some that may appear in other mucocutaneous diseases, some of which are very rare, such as chronic desquamative gingivitis (CDG) (26,27). However, CDG is a non-specific skin disease, and it is often difficult to differentiate from other dermatological conditions that present with a similar appearance. CDG is characterized by a chronic, progressive, and often progressive course, with episodes of exacerbation and remission. CDG is often associated with systemic diseases, such as autoimmune disorders, connective tissue diseases, and immune-mediated inflammatory disorders. The disease is more common in women and usually presents with a bilateral, symmetrical distribution of lesions on the hard and soft tissues of the oral cavity. The typical clinical presentation is characterized by the presence of prominent, white, reticular, band-like, and sometimes confluent lesions, often involving the gingiva, palate, and buccal mucosa. These lesions are usually painless, and their appearance and severity can vary over time. The diagnosis of CDG is often challenging, as it can mimic other oral diseases, such as lichen planus, pemphigus vulgaris, and erythema multiforme. In most cases, CDG is diagnosed on the basis of clinical features and histological examination. A biopsy is usually required for definitive diagnosis, as it shows the characteristic features of CDG, such as intraepithelial lymphocytosis and inflammatory changes in the underlying tissue. The treatment of CDG is often directed towards the underlying systemic disease, if present, and may include systemic medications and/or topical therapies, such as corticosteroids and immunosuppressants. Despite the presence of systemic manifestations, CDG is often a chronic, self-limiting condition, with a variable course and response to treatment.
al. (28), in 2000, on the other hand, observed a series of 723 patients with OLP and identified 336 (48%) cases of gingival involvement, out of which a total of 24 (7.4%) showed severe symptoms.

-Etiology
The etiology of lichen planus remains unknown. The existence of a family history can suggest a possible genetic predisposition (29). Gene polymorphisms of different HLA markers, as well as inflammatory cytokines and chemokines have been associated with the presence of LP. The cause of these polymorphisms, although it is not clear, supports the autoantigen hypothesis (13). Different authors have linked the onset, development and relapse of OLP, to stress, anxiety and depression (30,31).

In the pathogenesis there are also phenomenon involved that are of immunological nature, systemic diseases like diabetes, hypertension and chronic liver disease, mainly hepatitis C (14,25,31-33); all of which will be detailed in the following section.

-Relationship with Systemic Diseases
Many studies that have been carried out over the last few years have focused on the relationship between OLP and the hepatitis C virus (HCV) (4,14,25,33-34). Research studies performed in Spain (35), the USA (36), Italy (28), Japan (37), China (38) and Brazil (4,39) have found a significantly greater prevalence of the HCV infection in patients with OLP when compared to the control groups. Lodi et al. (2010) (34) published a meta-analysis and in their review they confirmed the association between the HCV infection and lichen planus. Based on this research, patients with LP have a risk that is approximately five times greater than that of the control groups for HCV seropositivity, but if we only focus on patients with OLP, the results are not significant (34).

Another interesting fact is that the results that demonstrate this strong association are usually found in geographical areas that are considered hyper endemic areas of HCV. No association has been found in geographical areas with low prevalence of HCV, like India, where a prevalence of 1.8% has been reported (40,41). The general prevalence of liver disease in lichen planus is from 0.1% to 35%, with a greater prevalence in patients that are in their 50s. In these patients the erosive variant of OLP is predominant (52%) and the most reported form of hepatitis is the chronic active presentation (42). The pathogenesis for this association is not clear, but it could be due to the cell-mediated cytotoxicity. Thus, the study performed by Femiano and Scully (2005) (43) suggests the possibility that HCV exerts an indirect effect through the induction of cytokines and lymphokines. Tovaru et al. (2013) (44), in a study in which 633 patients with OLP were evaluated, as well as the relationship with liver profiles, found that 24% of the patients with lichen planus showed some type of liver anomaly, and of this group, 9.64% were affected by the hepatitis C virus. In 2006, Lodi (45) carried out a review including data relating to HCV in patients with OLP and he reported high rates of prevalence of HCV in individuals with OLP. There was a significant relationship between HCV infection and manifestation of OLP found by De Carli et al. (2016) in a study carried out in Southern Brazil. Age, sex, systemic diseases and drugs were not identified as risk factors for the development of these diseases (4).

The association between lichen planus and cardiovascular risk factors is related to chronic systemic inflammation (46-49). The other hand, the link between oral lichen planus and dyslipidemia seems to pique the interest of researchers. Various research studies have found a greater prevalence of dyslipidemia in patients with LP, and such studies therefore indicate that the patients with the disease should undergo analytical evaluations (46-49). We must also remember that the presence of dyslipidemia in addition to other risk factors such as hypertension, diabetes mellitus, smoking and kidney disease is very frequent and such factors increase cardiovascular events (46). Lopez-Jornet et al., in 2013 (50) assessed 130 patients with OLP, they found that these patients predominantly suffered from diseases of the musculoskeletal system (22.3%), followed by anxiety and depression (21.5%). Hypertension was observed in 19.2% of the cases, while diabetes type 2 was found in 11.5%. The hypercholesterolemia was found in the 11.5% of patients and hypothyroidism in just 1.5%. The authors sought the association between OLP and autoimmune diseases, but their results did not concur with the previous hypothesis. The possible link between celiac disease and OLP is backed by Jokinen et al. (1998) (51), in their study carried out in 1998. In their research they reveal that of the 39 OLP patients, 22 presented CD positive antibodies. However, Scully et al. (1993) (52) did not diagnose celiac disease in any of the 103 patients that were studied, concluding that the association might just be accidental.

As of many years ago it has been suggested that the patients with OLP showed a greater incidence of diabetes than that of the general population (53). The link between OLP and diabetes is controversial, since more than one author (53,54) has indicated that an altered response to the oral administration of glucose exists in patients with LP; since some glycemia curves and insulin responses were obtained that are comparable to the ones that appear in type 2 diabetes. In reference to this matter, Giménez-García and Pérez-Castrillón (2004) (55) found that 10% of the patients assessed in their study were diagnosed with diabetes mellitus and 30% reported a family history of diabetes. We have already mentioned the study by Tovaru et al., in 2013 (44) where they assessed 633 patients with OLP, out of which 10% presented cases of type 2 diabetes. Lundström (1983) (56) found that 28% of the patients with OLP were diabetic, meanwhile in the group of individuals without OLP, only 3% suffice.
red from diabetes. However, Munde et al. (2013) (57), found that only 2.4% of their series presented cases of DM. In the population with DM the incidence of lichen planus was 1.6% (58).

The importance that is attributed to psychological factors varies according to the authors. There is controversy about whether or not psychiatric disorders are involved in the genesis of the disease or if it is the result of the presence of chronic painful lesions. In the controlled study carried out by Hirota et al. (2013) (59) the influence of psychological disorders (anxiety and depression) in oral lichen planus was evaluated. The results did not seem to support the idea that anxiety or depression have a role in the development of OLP lesions (59). Rojo-Moreno et al. (1998) (30), linked the most symptomatic erosive forms of OLP to stress and anxiety, these authors concluded that patients with oral lichen planus seem to suffer from a greater degree of anxiety and depression. Anxiety or emotional factors would be capable of making the disease chronic, or influencing the apparition of clinical forms that are predominantly red, more symptomatic and more complicated to manage for the clinician (60). Therefore, besides being a possible risk factor, the psychosomatic factors could aggravate the lesions (61). The results of the study carried out by Blanco-Carrion (2002) (31) reflect that psychosomatic alterations, hypercholesterolemia, diabetes and liver disease are frequently associated with patients with OLP. 8.4% of the patients had cutaneous lesions. All of these associations were more frequent in the red clinical forms of oral lichen planus. Anxiety, depression and somatization presented higher values than in the control group; however anxiety had significantly higher values in patients with red lichen. On the other hand, patients with lichen planus reported frequent worsening of their disease throughout periods of stress (7). A study carried out in 1996 by Burkhart et al. (1996) (62) proved that 51.4% of the patients with OLP perceived stressful situations in their lives, related to work, personal relationships and losses, which were alterations that occurred before and during the progression of the disease. In this regard, the authors proposed the idea of a link between stress and OLP (62). In 2009, Pokupec et al. (63), concluded that specialized attention might be necessary for patients with concomitant psychopathology with respect to lichen planus, particularly those with symptoms of depression, stress and anxiety.

Conclusions

Oral lichen planus is a chronic mucocutaneous disease with multifactorial etiology and pathogenesis. Several factors have been associated with OLP. Its association with HCV and other diseases that tend to be linked to LP is controversial and in need of further research. Clinically speaking, the disease undergoes periods of remission and exacerbation and all patients must be properly monitored. Periodic follow-up of all patients with OLP is recommended. Patients with OLP are carriers of a disease with systemic implications and may need the care of a multidisciplinary team. The correct diagnosis of any pathology is critical to making effective treatment and minimizes iatrogenic harm. For OLP is no different, taking into account its association with numerous systemic diseases that require special attention from health professionals.

References

1. Carrozzo M, Thorpe R. Oral lichen planus: a review. Minerva Stomatol. 2009;58:519-37.
2. Krupaa RJ, Sankari SL, Masthan KM, Rajesh E. Oral lichen planus: An overview. J Pharm Bioallied Sci. 2015;7:S158-61.
3. Van der Wall I. Oral lichen planus and oral lichenoid lesions: a critical appraisal with emphasis on the diagnostic aspects. Medicina Oral, Patología Oral y Cirugía Bucal. 2009;14:310-4.
4. De Carl JP, Linden MS, da Silva SO, Trentin MS, Matos Fde S, Paranhos LR. Hepatitis C and Oral Lichen Planus: Evaluation of their Correlation and Risk Factors in a Longitudinal Clinical Study. J Contemp Dent Pract. 2016;17:27-31.
5. Bascones-Martinez A, Mu-oz-Corcuera M, Bascones-llndains C. Immunological diseases of buccal localisation. Medicina Clínica (Barcelona). 2013;140:88-92.
6. Bascones-Martinez A, Figuero-Ruiz E, Esparza-Gómez GC. Oral ulcers. Medicina Clinica (Barcelona). 2005;125:590-7.
7. Blanco-Carrion A, Otero-Rey E, Peñamaría-Mallón M, Diniz-Freitas M. Diagnóstico del liquen plano oral. Avances en Odontostomatología. 2008;24:11-31.
8. Hirota SK, Moreno RA, dos Santos CH, Seo J, Migliari DA. Analysis of a possible association between oral lichen planus and drug intake. A controlled study. Medicina Oral Patología Oral y Cirugía Bucal. 2011;16:e750-6.
9. Bascones-Martinez A, Mattila R, Gomez-Font R, Meurman JH. Immunomodulatory drugs: oral and systemic adverse effects. Medicina Oral Patología Oral y Cirugía Buca. 2014;19:e24-31.
10. Srinivas K, Aravinda K, Ratnakar P, Nigam N, Gupta S. Oral lichen planus - Review on etiopathogenesis. National Journal of Maxillofacial Surgery. 2011;2:15-6.
11. Otero-Rey EM, Suarez-Alén F, Pe-amaria-Mallon M, Lopez-Lopez J, Blanco-Carrion A. Malignant transformation of oral lichen planus by a chronic inflammatory process. Use of topical corticosteroids to prevent this progression? Acta Odontologica Scandinavica. 2014;22:1-8.
12. Baird A, Lawrence J. Guidelines: is bigger better? A review of SIGN guidelines. BMJ Open. 2014;4:1-5.
13. Gorouhi F, Davari P, Fazeli N. Cutaneous and mucosal lichen pla- nus: a comprehensive review of clinical subtypes, risk factors, diagno- sis, and prognosis. Scientific World Journal. 2014;2014:742826.
14. Setlur K, Yerlagudda K. Oral lichenoid lesions - a review and update. Indian J Dermatol. 2015;60:102.
15. Blanco A, Gandara JM, Rodriguez A, Garcia A, Rodriguez I. Alte- raciones bioquimicas y su correlación clínica con el liquen plano oral. Medicina Oral. 2000;5:238-49.
16. Horowitz MR, Vidal Mde L, Resende MO, Teixeira MA, Cavalcanti SM, Alencar ER. Linear lichen planus in children--case report. Brazilian Annals of Dermatology. 2013;88:139-42.
17. Moger G, Thippanna CK, Kenchappa M, Puthalingaiah VD. Erosi- ve oral lichen planus with cutaneous involvement in a 7-year-old girl: a rare case report. Journal of Indian Society of Pedodontics and Preven- tive Dentistry. 2013;31:197-200.
18. Mollaoglu N. Oral lichen planus: a review. British Journal of Oral and Maxillofacial Surgery. 2000;38:370-77.
19. Arisawa EA, Almeida JD, Carvalho YR, Cabral LA. Clinicopatho- logical analysis of oral mucous autoimmune disease: A 27-year study. Medicina Oral Patología Oral y Cirugía Bucal. 2008;13:94-7.
20. Xue JL, Fan MW, Wang SZ, Chen XM, Li Y, Wang L. A clinical
study of 674 patients with oral lichen planus in China. Journal of Oral Pathology & Medicine. 2005;34:467-72.

21. Robledo-Sierra J, van der Waal I. How general dentists could manage a patient with oral lichen planus. Med Oral Patol Oral Cir Bucal. 2018;23:e198-202.

22. Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: study of 723 patients. Journal of the American Academy of Dermatology. 2002;46:207-14.

23. Kaplan I, Ventura-Sharabi Y, Gal G, Calderon S, Anavi Y. The dynamics of oral lichen planus: a retrospective clinicopathological study. Head & Neck Pathology. 2012;6:178-83.

24. Warnaokusiriya S, Johnson NW, Van der Wall I. Nomenclature and classification of potentially malignant disorders of the mucosa. Journal of Oral Pathology & Medicine. 2007;36:575-80.

25. Bagán JV, Millan MA, Pebarrocha M, Jiménez Y. A clinical study of 205 patients with oral lichen planus. Journal of Oral and Maxillofacial Surgery. 1992;50:116-8.

26. Lo Russo L, Fiero G, Guiglia R, Compilato D, Testa NF, Lo Muzio L, et al. Epidemiology of desquamative gingivitis: evaluation of 125 patients and review of the literature. International Journal of Dermatology. 2009;48:1049-52.

27. Bermejo-Fenoll A, Sánchez-Siles M, López-Jornet P, Cama-choco-Alonso F, Salazar-Sánchez N. A retrospective clinicopathological study of 550 patients with oral lichen planus in south-eastern Spain. Journal of Oral Pathology & Medicine. 2010;39:491-96.

28. Mignogna MD, Lo Muzio L, Lo Russo L, Fedele S, Ruoppo E, Bucci E. Oral lichen planus: different clinical features in HCV-positive and HCV-negative patients. International Journal of Dermatology. 2008;47:334-9.

29. Bermejo-Fenoll A, Lopez-Jornet F. Familial oral lichen planus: presentation of six families. Oral Surgery, Oral Medicine, and Oral Pathology. 2006;102: E12-E15.

30. Rojo-Moreno JL, Bagán JV, Rojo-Moreno J, Donat JS, Millan MA, Jimenez Y. Psychologic factors and oral lichen planus. A psychometric evaluation of 100 cases. Oral Surgery, Oral Medicine, and Oral Pathology. 1998;86:687-91.

31. Blanco-Carrión A. Patología sistémica y manifestaciones cutáneas en el liquen plano oral. Archivos de Odontostomatología. 2002;18:562-71.

32. Di Stasio D, Guida A, Salerno C, Contaldo M, Esposito V, Laino L, Serpico R, Luhecse A. Oral lichen planus: a narrative review. Frontiers in bioscience. 2014;6:370-6.

33. Carrozzo M, Scally K. Oral manifestations of hepatitis C virus infection. World Journal of Gastroenterology. 2002;8:259-66.

34. Rojo-Moreno JL, Bagán JV, Rojo-Moreno J, Donat JS, Millan MA, Jimenez Y. Psychologic factors and oral lichen planus. A psychometric evaluation of 100 cases. Oral Surgery, Oral Medicine, and Oral Pathology. 1998;86:687-91.

35. Blanco-Carrión A. Patología sistémica y manifestaciones cutáneas en el liquen planooral. Archivos de Odontoestomatología. 2002;18:562-71.

36. Di Stasio D, Guida A, Salerno C, Contaldo M, Esposito V, Laino L, Serpico R, Lucches A. Oral lichen planus: a narrative review. Frontiers in bioscience. 2014;6:370-6.

37. Nagao Y, Sata M, Noguchi S, Seno’o T, Kinoshita M, Kameya ma T, et al. Detection of hepatitis C virus RNA in oral lichen pla-nus and oral cancer tissues. Journal of Oral Pathology & Medicine. 2000;29:259-66.

38. Chang JY, Chiang CP, Hsiao CK, Sun A. Significantly higher frequencies of presence of serum autoantibodies in Chinese patients with oral lichen planus. Journal of Oral Pathology & Medicine. 2009;38:48-54.

39. Figueiredo LC, Carrilho FJ, de Andrade HF, Migliari DA. Oral lichen planus and hepatitis C virus infection. Oral Diseases. 2002;8:42-6.

40. Kumar KPM, Joss HS, Hallikerimuth S, Kale AD. Oral Lichen Pla-nus: An Extraphatic Manifestation of Viral Hepatitis – Evaluation in Indian Subpopulation. Journal of Clinical and Diagnostic Research. 2013;7:2068-9.

41. Sy T, Jamal MM. Epidemiology of Hepatitis C Virus (HCV) Infection. International Journal of Medical Sciences. 2006;3:41-6.

42. Jiménez-García R, Pérez-Castrillón JL. Liquen plano y enfermeda-des hepáticas. Piel. 2002;17:348-52.

43. Femiao F, Scully C. Functions of the cytokines in relation oral li-chen planus-hepatitis C. Medicina Oral Patología Oral y Cirugía Bucal. 2005;10:e40-4.

44. Tovaru S, Parlatescu I, Gheorge C, Tovaru M, Costache M, Sar-della A. Oral lichen planus: A retrospective study of 633 patients from Bucharest, Romania. Medicina Oral Patología Oral y Cirugía Bucal. 2013;18:e201-6.

45. Lodi G. Hepatitis C virus and lichen planus. Journal of Eviden-ce-Based Dentistry. 2006;7:18.

46. Dreier J, Shapiro J, Cohen AD. Lichen planus and dyslipidaemia: a case-control study. British Journal of Dermatology. 2009;161:626-9.

47. Arias-Santiago S, Buendia-Eisman A, Aneiros-Fernández J, Gí-rón-Prieto MS, Gutiérrez-Salmerón MT, Mellado VG, et al. Cardiovascular risk factors in patients with lichen planus. American Journal of Medicine. 2011;124:543-8.

48. Arias-Santiago S, Buendia-Eisman A, Aneiros-Fernández J, Gí-rón-Prieto MS, Gutiérrez-Salmerón MT, Garcia-Mellado V, et al. Lipid levels in patients with lichen planus: a case-control study. Journal of the European Academy of Dermatology and Venereology. 2011;25:1398-401.

49. López-Jornet P, Camacho-Alonso F, Rodriguez-Martínes MA. Alterations in serum lipid profile patterns in oral lichen planus: a cross-sectional study. American Journal of Clinical Dermatology. 2012;13:399-404.

50. López-Jornet P, Parra-Perez F, Pons-Fuster A. Association of autoimmune diseases with oral lichen planus: a cross-sectional, clinical study. Journal of European Academy of Dermatology and Venereology. 2014;28:895-9.

51. Johkina J, Peters U, Mäki M, Miettinen A, Collin P. Celiac sprue in patients with chronic oral mucosal symptoms. Journal of Clinical Gastroenterology. 1998;26:23-6.

52. Scully C, Porter SR, Eveson JW. Oral lichen planus and celiac disease. Lancet. 1993;341:1660.

53. Lowe NJ, Cudworth AG, Clough SA, Bullen MF. Carbohydrate metabolism in lichen planus. British Journal of Dermatology. 1976;95:9-12.

54. Powell SM, Ellis JP, Ryan TJ, Vickers HR. Glucose tolerance in lichen planus. British Journal of Dermatology. 1974;1:73-5.

55. Giménez-García R; Pérez-Castrillón JL. Liquen plano y enfermedades asociadas: estudio clínicoepidemiológico. Actas Dermosifilográficas. 2004;95:154-60.

56. Lundström IM. Incidence of diabetes mellitus in patients with oral lichen planus. International Journal of Oral & Maxillofacial Surgery. 1983;12:147-52.

57. Munde AD, Karle RR, Wankheede PK, Shaikh SS, Kulkurni M. Demographic and clinical profile of oral lichen planus: A retrospective study. Contemporary Clinical Dentistry. 2013;4:181-5.

58. Jelinek JE. Cutaneous manifestations of diabetes mellitus. Interna-tional Journal of Dermatology. 1994;34:605-17.

59. Hirota SK, Moreno RA, Dos Santos CH, Seo J, Migliari DA. Psy-chological profile (anxiety and depression) in patients with oral lichen planus: a controlled study. Minerva Stomatologica. 2013;62:51-6.

60. Chaudhary S. Psychosocial stressors in patients with oral lichen planus. Australian Dental Journal. 2004;49:192-5.

61. García-Pola MJ, Huerta-Zarabozo G. Valoración de la ansiedad como factor etiológico del liquen plano oral. Medicina Oral. 2000;5:7-13.

62. Burkhart NW, Burke EJ, Burkes EJ, Wolfe L. Assessing the cha-racteristics of patients with oral lichen planus. Journal of the American Dental Association. 1996;127:648-56.

63. Pokucuz JS, Gruden V, Gruden V Jr. Lichen ruber planus as a psy-chiatric problem. Psychiatria Danubina. 2009;21:514-6.

Conflicts of Interest

None.